HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (May.26)- 9th National VBP, China's Strength in ADC Field, Ovctek, Eyebright

China Healthcare Weekly (Jun.16)- 9th National VBP Update, “Noise” of Consumption Upgrading, ChatGPT

China Healthcare Weekly (Jun.23) - National TCM VBP Results, CDE Changes Game Rule, Hua Medicine

2022 High Conviction (China Healthcare) - Seek the Relative Certainties Out of the Uncertainties

Investment Opportunities in China Medical Device Industry

Eyebright Medical Technology (688050.CH) -The Impact Of Centralized Procurement and Business Outlook

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

<ul>
<li>In “<em>Investment opportunity in China healthcare industry</em>” we analyzed <a href="https://www.smartkarma.com/entities/ovctek-china-inc" target="_blank" data-smartkarma-citation="entities:29638:1" rel="noopener">Ovctek China Inc (300595 CH)</a>.</li>
<li>However, the stock price has fallen about 43% so far from the record high of RMB109.7/share in June.</li>
<li>Before investors decide to take advantage of this correction, it would be better to look at some potential risks of OVCTEK.</li>
</ul>


In “Investment opportunity in China healthcare industry” we analyzed Ovctek China Inc (300595 CH).
However, the stock price has fallen about 43% so far from the record high of RMB109.7/share in June.
Before investors decide to take advantage of this correction, it would be better to look at some potential risks of OVCTEK.


Shanghai Haohai Biological Technology (6826 HK)

Ovctek China Inc (300595.CH) - Better See Some Potential Risks Before Making Decisions